Tamara Seredenina, PhD, has more than 15 years of experience in discovery and preclinical validation of new drug targets for neurodegenerative disorders both in industry and academic settings. She joined AC Immune in 2016 to lead the neuroinflammation program and explore the NLRP3 inflammasome pathway as target for discovery of novel therapeutics. Prior to this, as a senior researcher at the University of Geneva she explored the therapeutic potential of targeting neuroinflammation in amyotrophic lateral sclerosis. She led work within the European consortium (EU-ROS) responsible for generation and validation of assays and reference compounds to unravel the role of redox signaling in human disease. Earlier in her career she conducted identification and validation of new therapeutic targets for Huntington’s disease at the EPFL in Switzerland and for Alzheimer’s disease at SienaBiotech in Italy. She received her PhD from the Russian State Medical University in 2006.